View ValuationOctober PharmaE 将来の成長Future 基準チェック /06現在、 October PharmaEの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長13.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBoard Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). MD & Director Hesham Abdul Soliman was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Apr 06October Pharma S.A.E, Annual General Meeting, Apr 27, 2026October Pharma S.A.E, Annual General Meeting, Apr 27, 2026, at 15:30 Egypt Standard Time. Location: cairo EgyptBoard Change • May 14No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). Director Hesham Abdul Soliman was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • May 13October Pharma S.A.E, Annual General Meeting, May 31, 2025October Pharma S.A.E, Annual General Meeting, May 31, 2025, at 12:00 Egypt Standard Time. Location: cairo EgyptReported Earnings • Nov 16Third quarter 2024 earnings released: EPS: ج.م2.67 (vs ج.م4.09 in 3Q 2023)Third quarter 2024 results: EPS: ج.م2.67 (down from ج.م4.09 in 3Q 2023). Revenue: ج.م326.1m (up 24% from 3Q 2023). Net income: ج.م32.0m (down 35% from 3Q 2023). Profit margin: 9.8% (down from 19% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Sep 17New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 2.7% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (2.7% operating cash flow to total debt). Minor Risks Profit margins are more than 30% lower than last year (9.9% net profit margin). Market cap is less than US$100m (ج.م1.41b market cap, or US$29.1m).Valuation Update With 7 Day Price Move • Sep 17Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ج.م117, the stock trades at a trailing P/E ratio of 9.3x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 124% over the past three years.Reported Earnings • May 30First quarter 2024 earnings released: EPS: ج.م3.52 (vs ج.م2.94 in 1Q 2023)First quarter 2024 results: EPS: ج.م3.52 (up from ج.م2.94 in 1Q 2023). Revenue: ج.م274.4m (up 29% from 1Q 2023). Net income: ج.م50.1m (up 42% from 1Q 2023). Profit margin: 18% (up from 17% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • May 21Upcoming dividend of ج.م2.50 per shareEligible shareholders must have bought the stock before 28 May 2024. Payment date: 30 May 2024. The company last paid an ordinary dividend in April 2017. The average dividend yield among industry peers is 3.3%.Reported Earnings • Mar 16Full year 2023 earnings released: EPS: ج.م12.53 (vs ج.م9.48 in FY 2022)Full year 2023 results: EPS: ج.م12.53 (up from ج.م9.48 in FY 2022). Revenue: ج.م1.01b (up 39% from FY 2022). Net income: ج.م182.1m (up 39% from FY 2022). Profit margin: 18% (in line with FY 2022). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Oct 01New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (ج.م1.20b market cap, or US$38.8m).Valuation Update With 7 Day Price Move • Dec 21Investor sentiment improved over the past weekAfter last week's 19% share price gain to ج.م95.30, the stock trades at a trailing P/E ratio of 9.5x. Average trailing P/E is 5x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 210% over the past three years.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 9 non-independent directors. Director Hesham Abdul Soliman was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 9 non-independent directors. Director Hesham Abdul Soliman was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Upcoming Dividend • Apr 13Upcoming dividend of ج.م4.00 per shareEligible shareholders must have bought the stock before 20 April 2022. Payment date: 26 April 2022. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of Egyptian dividend payers (11%). Lower than average of industry peers (4.0%).Reported Earnings • Jun 19First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ج.م165.8m (up 38% from 1Q 2020). Net income: ج.م40.6m (up 402% from 1Q 2020). Profit margin: 25% (up from 6.7% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Jun 02Inaugural dividend of ج.م3.00 per shareEligible shareholders must have bought the stock before 09 June 2021. Payment date: 13 June 2021. The company last paid an ordinary dividend in May 2018. The average dividend yield among industry peers is 4.2%. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、October PharmaE は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測CASE:OCPH - アナリストの将来予測と過去の財務データ ( )EGP Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/20251,462165356371N/A6/30/20251,413141309332N/A3/31/20251,3401384775N/A12/31/20241,228131-1043N/A9/30/20241,193158-2624N/A6/30/20241,130175-2715N/A3/31/20241,073172104151N/A12/31/20231,012150118153N/A9/30/20238911312276N/A6/30/2023809117-7626N/A3/31/2023761110-110-4N/A12/31/2022727114-187-92N/A9/30/2022709114-6221N/A6/30/2022695105108150N/A3/31/2022669111222246N/A12/31/2021655120241262N/A9/30/2021651123161174N/A6/30/20216191319397N/A3/31/20215891214448N/A12/31/2020543884653N/A9/30/202052779116N/A6/30/2020527623348N/A3/31/2020529383448N/A12/31/2019523346396N/A9/30/2019499176594N/A6/30/20194628N/A-30N/A3/31/201942618N/A-114N/A12/31/201840118N/A-50N/A9/30/201835521N/A-15N/A6/30/201833925N/A11N/A3/31/201834634N/A68N/A12/31/201735045N/A-31N/A9/30/201735152N/A-24N/A6/30/201733750N/A16N/A3/31/201730242N/A36N/A12/31/201628835N/A82N/A9/30/201626624N/A90N/A6/30/201625619N/A57N/A3/31/201625820N/A32N/A12/31/201524416N/A16N/A9/30/201523922N/A13N/A6/30/201523117N/A14N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: OCPHの予測収益成長が 貯蓄率 ( 15.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: OCPHの収益がEG市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: OCPHの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: OCPHの収益がEG市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: OCPHの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: OCPHの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 04:10終値2026/05/21 00:00収益2025/09/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋October Pharma S.A.E 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). MD & Director Hesham Abdul Soliman was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Apr 06October Pharma S.A.E, Annual General Meeting, Apr 27, 2026October Pharma S.A.E, Annual General Meeting, Apr 27, 2026, at 15:30 Egypt Standard Time. Location: cairo Egypt
Board Change • May 14No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). Director Hesham Abdul Soliman was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • May 13October Pharma S.A.E, Annual General Meeting, May 31, 2025October Pharma S.A.E, Annual General Meeting, May 31, 2025, at 12:00 Egypt Standard Time. Location: cairo Egypt
Reported Earnings • Nov 16Third quarter 2024 earnings released: EPS: ج.م2.67 (vs ج.م4.09 in 3Q 2023)Third quarter 2024 results: EPS: ج.م2.67 (down from ج.م4.09 in 3Q 2023). Revenue: ج.م326.1m (up 24% from 3Q 2023). Net income: ج.م32.0m (down 35% from 3Q 2023). Profit margin: 9.8% (down from 19% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Sep 17New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 2.7% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (2.7% operating cash flow to total debt). Minor Risks Profit margins are more than 30% lower than last year (9.9% net profit margin). Market cap is less than US$100m (ج.م1.41b market cap, or US$29.1m).
Valuation Update With 7 Day Price Move • Sep 17Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ج.م117, the stock trades at a trailing P/E ratio of 9.3x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 124% over the past three years.
Reported Earnings • May 30First quarter 2024 earnings released: EPS: ج.م3.52 (vs ج.م2.94 in 1Q 2023)First quarter 2024 results: EPS: ج.م3.52 (up from ج.م2.94 in 1Q 2023). Revenue: ج.م274.4m (up 29% from 1Q 2023). Net income: ج.م50.1m (up 42% from 1Q 2023). Profit margin: 18% (up from 17% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • May 21Upcoming dividend of ج.م2.50 per shareEligible shareholders must have bought the stock before 28 May 2024. Payment date: 30 May 2024. The company last paid an ordinary dividend in April 2017. The average dividend yield among industry peers is 3.3%.
Reported Earnings • Mar 16Full year 2023 earnings released: EPS: ج.م12.53 (vs ج.م9.48 in FY 2022)Full year 2023 results: EPS: ج.م12.53 (up from ج.م9.48 in FY 2022). Revenue: ج.م1.01b (up 39% from FY 2022). Net income: ج.م182.1m (up 39% from FY 2022). Profit margin: 18% (in line with FY 2022). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Oct 01New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (ج.م1.20b market cap, or US$38.8m).
Valuation Update With 7 Day Price Move • Dec 21Investor sentiment improved over the past weekAfter last week's 19% share price gain to ج.م95.30, the stock trades at a trailing P/E ratio of 9.5x. Average trailing P/E is 5x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 210% over the past three years.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 9 non-independent directors. Director Hesham Abdul Soliman was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 9 non-independent directors. Director Hesham Abdul Soliman was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • Apr 13Upcoming dividend of ج.م4.00 per shareEligible shareholders must have bought the stock before 20 April 2022. Payment date: 26 April 2022. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of Egyptian dividend payers (11%). Lower than average of industry peers (4.0%).
Reported Earnings • Jun 19First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ج.م165.8m (up 38% from 1Q 2020). Net income: ج.م40.6m (up 402% from 1Q 2020). Profit margin: 25% (up from 6.7% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Jun 02Inaugural dividend of ج.م3.00 per shareEligible shareholders must have bought the stock before 09 June 2021. Payment date: 13 June 2021. The company last paid an ordinary dividend in May 2018. The average dividend yield among industry peers is 4.2%.